Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
380 stopped studies mapped to Malignant Uterine Neoplasm and descendants · 86% state a reason
Over the 380 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05798611 | Study of ART0380 in Patients With Biologically Selected Solid Tumors(ARTIST) | Phase 2 | terminated | Apr 4, 2023 | Artios Pharma Ltd | Sponsor decision, not for reasons affecting the benefit-risk balance. | Sponsor / business decision |
| NCT05169437 | Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors(PAVO) | Phase 2 | terminated | Dec 27, 2021 | Tempus AI | Recruitment challenges | Enrollment / accrual |
| NCT05229601 | A Study of HFB301001 in Adult Patients With Advanced Solid Tumors | Phase 1 | terminated | Feb 8, 2022 | HiFiBiO Therapeutics | The decision to discontinue the trial was made as part of a strategic review of the Sponsor's… | Safety / toxicity |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in… | Phase 1 | terminated | Feb 17, 2020 | Incyte Corporation | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT05483023 | 18-fluorofuranylnorprogesterone (FFNP) PET/MRI as a Potential Biomarker of Response to… | Phase 2 | withdrawn | Aug 1, 2022 | UNC Lineberger Comprehensive Cancer Center | Drug cannot be produced and scanner down. | Other (stated, no rule matched) |
| NCT05263492 | Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent… | Phase 2 | terminated | Mar 2, 2022 | Virginia Commonwealth University | Closed early due to low enrollment rates | Enrollment / accrual |
| NCT06264921 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | Phase 1 | terminated | Feb 20, 2024 | NiKang Therapeutics, Inc. | This study was terminated as a result of Sponsor portfolio reprioritization. | Sponsor / business decision |
| NCT06058728 | A Study to Evaluate Changes in Hair in Adult Participants Taking Oral Oriahnn Capsules…(Pink Orchid) | — | withdrawn | Sep 28, 2023 | AbbVie | Company Decision | Sponsor / business decision |
| NCT02554565 | Innovation for Standard Identification of Insertional HPV Mutations and of Target…(PAIR HPV) | N/A | terminated | Sep 18, 2015 | Institut Curie | Study in competition with another so it was decided to stop recruitment | Enrollment / accrual |
| NCT06321068 | BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line… | Phase 2 / Phase 3 | terminated | Mar 20, 2024 | Bio-Thera Solutions | Due to the adjustment of our company's research and development strategy, we are now prematurely… | Sponsor / business decision |
| NCT04159155 | A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer(CAN-STAMP) | Phase 2 / Phase 3 | terminated | Nov 12, 2019 | University Health Network, Toronto | Low accrual | Enrollment / accrual |
| NCT05017246 | Comparing Intrathecal Morphine and Intraoperative Lidocaine Infusion to Epidural… | Phase 2 | terminated | Aug 23, 2021 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT05124743 | HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T… | — | terminated | Nov 18, 2021 | Alaunos Therapeutics | TCR001-002 protocol was combined with TCR001-201 protocol, which was terminated due to business… | Sponsor / business decision |
| NCT03194646 | Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids(ASTEROID 6) | Phase 3 | terminated | Jun 21, 2017 | Bayer | Due to a change in the development program, the study was closed prematurely. | Other (stated, no rule matched) |
| NCT06299163 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Mar 7, 2024 | Numab Therapeutics AG | Business decision | Sponsor / business decision |
| NCT02140021 | Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer… | N/A | terminated | May 16, 2014 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT04116320 | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors(AM-003) | Phase 1 | terminated | Oct 4, 2019 | Craig L Slingluff, Jr | Unable to enroll enough patients to complete targeted enrollment in a reasonable time. | Enrollment / accrual |
| NCT04577963 | A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Oct 8, 2020 | Hutchmed | At the time of study termination, both fruquintinib and tislelizumab are commercially available in… | Other (stated, no rule matched) |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | Phase 2 | terminated | Oct 3, 2022 | Telix Pharmaceuticals (Innovations) Pty Ltd | Indication scouting for TLX250-CDx will continue in theranostic studies, with a therapeutic… | Other (stated, no rule matched) |
| NCT05274451 | A Study to Investigate LYL797 in Adults With Solid Tumors | Phase 1 | terminated | Mar 10, 2022 | Lyell Immunopharma, Inc. | Pipeline Reprioritization | Other (stated, no rule matched) |
| NCT05891197 | A Biomarker Screening Protocol for Participants With Solid Tumors(START) | — | terminated | Jun 6, 2023 | Lyell Immunopharma, Inc. | Pipeline Reprioritization | Other (stated, no rule matched) |
| NCT06393751 | Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment… | Phase 1 / Phase 2 | withdrawn | May 1, 2024 | National Cancer Institute (NCI) | Other - Protocol moved to Withdrawn | Other (stated, no rule matched) |
| NCT03277482 | Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer | Phase 1 | terminated | Sep 11, 2017 | Dana-Farber Cancer Institute | Expansion cohort was not open | Other (stated, no rule matched) |
| NCT02446652 | Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer | Phase 3 | withdrawn | May 18, 2015 | National Institute of Cancerología | Due to a lack of sufficient resources, the opening was not carried out. | Other (stated, no rule matched) |
| NCT04152018 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | Phase 1 | terminated | Nov 5, 2019 | Pfizer | Study termination was based on strategic considerations and not due to specific safety reasons or a… | Safety / toxicity |
| NCT03255252 | Assessment Study to Evaluate Specific Immune Response in Locally Advanced Cervix Cancer…(IMMUVIX) | Phase 2 | terminated | Aug 21, 2017 | Institut du Cancer de Montpellier - Val d'Aurelle | insufficient recruitment | Enrollment / accrual |
| NCT05396794 | Bariatric Education for Women With Obesity and Endometrial Cancer(SCC-BAREDU) | — | terminated | May 31, 2022 | University of Oklahoma | No Surgeon to perform the operations. | Other (stated, no rule matched) |
| NCT05462249 | Impact of Catch-up HPV Vaccination(HPVAC2) | — | terminated | Jul 18, 2022 | University Hospital, Brest | overestimation of the number of healthcare professionals participating in the inclusions | Other (stated, no rule matched) |
| NCT04483544 | Pembrolizumab and Olaparib in Cervical Cancer Patients | Phase 2 | terminated | Jul 23, 2020 | Baptist Health South Florida | Poor accrual related to change in standard of care treatment for this population. | Enrollment / accrual |
| NCT06106633 | Pain Reduction and Ovarian Perfusion Following Uterine Fibroid Embolization(PEDD-UFE) | N/A | terminated | Oct 30, 2023 | Massachusetts General Hospital | Insufficient Enrollment | Enrollment / accrual |
| NCT04301011 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors(RAPTOR) | Phase 1 | terminated | Mar 9, 2020 | Turnstone Biologics, Corp. | Sponsor decision | Sponsor / business decision |
| NCT04514692 | Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF… | Phase 1 / Phase 2 | terminated | Aug 17, 2020 | Stanford University | Lack of funding | Funding |
| NCT04278326 | Primary Organoid Models and Combined Nucleic Acids Therapeutics for Anti-HPV Treatments(ORGANOIDES) | N/A | terminated | Feb 20, 2020 | Centre Hospitalier Régional d'Orléans | the partner laboratory encountered various difficulties (COVID, relocation of the laboratory,… | COVID-19 / pandemic |
| NCT05179239 | A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102… | Phase 3 | terminated | Jan 5, 2022 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Sponsor develops strategy adjustment | Sponsor / business decision |
| NCT03527264 | BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the… | Phase 2 | terminated | May 17, 2018 | Brown University | Slow enrollment | Enrollment / accrual |
| NCT04383210 | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid… | Phase 2 | terminated | May 12, 2020 | Elevation Oncology | Business decision | Sponsor / business decision |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab… | Phase 1 / Phase 2 | terminated | Feb 4, 2019 | Kymab Limited | Early discontinuation based on strategic sponsor decision not driven by any safety concerns. | Safety / toxicity |
| NCT06385548 | Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol…(LiDer) | Phase 1 / Phase 2 | withdrawn | Apr 26, 2024 | Vall d'Hebron Institute of Oncology | IMP owner decision | Other (stated, no rule matched) |
| NCT05192850 | Endometrial Cancer Recurrence in Patients Taking Metformin | — | withdrawn | Jan 14, 2022 | WellSpan Health | study was not started at WellSpan | Other (stated, no rule matched) |
| NCT04889495 | A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in… | — | withdrawn | May 17, 2021 | Pfizer | The study was withdrawn due to global supply chain issue. Zirabev was not launching in Korea. | Drug supply |
| NCT05470309 | Community Outreach-based Study to Increase Cervical Cancer Screening Among Hispanic Women… | — | withdrawn | Jul 22, 2022 | MetroHealth Medical Center | Personnel departure. | Other (stated, no rule matched) |
| NCT04750941 | Study of Copanlisib and Ketogenic Diet | Phase 2 | terminated | Feb 11, 2021 | Columbia University | Enrollment challenges | Enrollment / accrual |
| NCT04906382 | Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer | Early Phase 1 | terminated | May 28, 2021 | Floor Backes, MD | Sponsor reorganization | Other (stated, no rule matched) |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | Phase 1 | terminated | Feb 5, 2020 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT04665921 | A Study of SGN-STNV in Advanced Solid Tumors | Phase 1 | terminated | Dec 14, 2020 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT06681870 | A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors | Phase 1 | withdrawn | Nov 8, 2024 | Astellas Pharma Global Development, Inc. | A business decision was made to not initiate this study. | Sponsor / business decision |
| NCT06752135 | Node Positive Cervical Cancer Treated by Neoadjuvant Chemotherapy Plus Radical Surgery: a…(HRCC1) | — | terminated | Dec 30, 2024 | Azienda Policlinico Umberto I | Retrospectively data collection complited | Other (stated, no rule matched) |
| NCT03099499 | Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer | Phase 2 | terminated | Apr 4, 2017 | Fox Chase Cancer Center | Slow accrual | Enrollment / accrual |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | Phase 1 / Phase 2 | terminated | Aug 15, 2022 | Aminex Therapeutics, Inc. | Required re-formulation of DFMO from IV to capsule to maintain safety | Safety / toxicity |
| NCT05289648 | Niraparib in High-grade Endometrial Cancer Trial(NIREC) | Early Phase 1 | withdrawn | Mar 21, 2022 | Sir Mortimer B. Davis - Jewish General Hospital | Unable to obtain funding | Funding |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Nov 6, 2025source: clinicaltrials